Acute Tubulointerstitial Nephritis: A Case Report on Rare Adverse Effect of Pembrolizumab

Pembrolizumab is a novel immune checkpoint inhibitor approved for use in non-small cell lung carcinoma. There have been a few cases that have associated adverse renal outcomes with pembrolizumab. We present a case of acute kidney injury in a patient on pembrolizumab who was noted to have acute tubul...

Descripción completa

Detalles Bibliográficos
Autores principales: Basnet, Sijan, Dhital, Rashmi, Tharu, Biswaraj
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6572507/
https://www.ncbi.nlm.nih.gov/pubmed/31117208
http://dx.doi.org/10.3390/medicina55050176
_version_ 1783427656697511936
author Basnet, Sijan
Dhital, Rashmi
Tharu, Biswaraj
author_facet Basnet, Sijan
Dhital, Rashmi
Tharu, Biswaraj
author_sort Basnet, Sijan
collection PubMed
description Pembrolizumab is a novel immune checkpoint inhibitor approved for use in non-small cell lung carcinoma. There have been a few cases that have associated adverse renal outcomes with pembrolizumab. We present a case of acute kidney injury in a patient on pembrolizumab who was noted to have acute tubulointerstitial nephritis on renal biopsy. Pembrolizumab was discontinued and the patient was started on long-term corticosteroids with a taper. Her renal function improved partially with treatment.
format Online
Article
Text
id pubmed-6572507
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-65725072019-06-18 Acute Tubulointerstitial Nephritis: A Case Report on Rare Adverse Effect of Pembrolizumab Basnet, Sijan Dhital, Rashmi Tharu, Biswaraj Medicina (Kaunas) Case Report Pembrolizumab is a novel immune checkpoint inhibitor approved for use in non-small cell lung carcinoma. There have been a few cases that have associated adverse renal outcomes with pembrolizumab. We present a case of acute kidney injury in a patient on pembrolizumab who was noted to have acute tubulointerstitial nephritis on renal biopsy. Pembrolizumab was discontinued and the patient was started on long-term corticosteroids with a taper. Her renal function improved partially with treatment. MDPI 2019-05-21 /pmc/articles/PMC6572507/ /pubmed/31117208 http://dx.doi.org/10.3390/medicina55050176 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Case Report
Basnet, Sijan
Dhital, Rashmi
Tharu, Biswaraj
Acute Tubulointerstitial Nephritis: A Case Report on Rare Adverse Effect of Pembrolizumab
title Acute Tubulointerstitial Nephritis: A Case Report on Rare Adverse Effect of Pembrolizumab
title_full Acute Tubulointerstitial Nephritis: A Case Report on Rare Adverse Effect of Pembrolizumab
title_fullStr Acute Tubulointerstitial Nephritis: A Case Report on Rare Adverse Effect of Pembrolizumab
title_full_unstemmed Acute Tubulointerstitial Nephritis: A Case Report on Rare Adverse Effect of Pembrolizumab
title_short Acute Tubulointerstitial Nephritis: A Case Report on Rare Adverse Effect of Pembrolizumab
title_sort acute tubulointerstitial nephritis: a case report on rare adverse effect of pembrolizumab
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6572507/
https://www.ncbi.nlm.nih.gov/pubmed/31117208
http://dx.doi.org/10.3390/medicina55050176
work_keys_str_mv AT basnetsijan acutetubulointerstitialnephritisacasereportonrareadverseeffectofpembrolizumab
AT dhitalrashmi acutetubulointerstitialnephritisacasereportonrareadverseeffectofpembrolizumab
AT tharubiswaraj acutetubulointerstitialnephritisacasereportonrareadverseeffectofpembrolizumab

Ejemplares similares